Howard G. Smith MD, AM on Instagram: "Swedish Scientists Have A New Pill That Burns Fat This new drug, in contrast to our current, popular diet medications, doesn’t curb your appetite but rather works on your body’s muscles to intensify fat burning and blood sugar control. Karolinska Institute molecular biologists, publishing in the journal Cell, show that their laboratory-designed beta-2 agonist activates metabolic pathways inside muscle tissue. In animal studies, this leads to improved blood sugar regulation, increased fat burning, and healthier body composition. Unlike the GLP-1 weight-loss drugs, the treatment does not appear to cause appetite suppression, muscle loss, or digestive side effects. The research team also completed an preliminary Phase I clinical trial involving 48 healthy volunteers and 25 people with type 2 diabetes. The treatment is safe and well tolerated. The researchers say preserving muscle mass may be the most important benefit of this alternative weight loss regimen because muscle plays a major role in metabolism, healthy aging, and overall life expectancy. Another potential advantage is convenience. Unlike some GLP-1 medications, that require injection, this therapy is an oral medication. The scientists also believe it could eventually be used either alone or alongside existing drugs such as Ozempic and Wegovy. At this time, beta-2 agonist therapy remains experimental though a larger Phase II trial is now planned. The question of the day: could future weight-loss treatments focus on selectively boosting metabolism instead of suppressing appetite? Upcoming studies should provide an answer. The references for this report are available on my website. #DiabetesResearch #WeightLossNews #ObesityResearch #HealthyAging #MedicalBreakthrough"

0 likes, 0 comments - drhowardsmithreports on June 21, 2026: "Swedish Scientists Have A New Pill That Burns Fat This new drug, in contrast to our current, popular diet medications, doesn’t curb your appetite but rather works on your body’s muscles to intensify fat burning and blood sugar control. Karolinska Institute molecular biologists, publishing in the journal Cell, show that their laboratory-designed beta-2 agonist activates metabolic pathways inside muscle tissue. In animal studies, this leads to improved blood sugar regulation, increased fat burning, and healthier body composition. Unlike the GLP-1 weight-loss drugs, the treatment does not appear to cause appetite suppression, muscle loss, or digestive side effects. The research team also completed an preliminary Phase I clinical trial involving 48 healthy volunteers and 25 people with type 2 diabetes. The treatment is safe and well tolerated. The researchers say preserving muscle mass may be the most important benefit of this alternative weight loss regimen because muscle plays a major role in metabolism, healthy aging, and overall life expectancy. Another potential advantage is convenience. Unlike some GLP-1 medications, that require injection, this therapy is an oral medication. The scientists also believe it could eventually be used either alone or alongside existing drugs such as Ozempic and Wegovy. At this time, beta-2 agonist therapy remains experimental though a larger Phase II trial is now planned. The question of the day: could future weight-loss treatments focus on selectively boosting metabolism instead of suppressing appetite? Upcoming studies should provide an answer. The references for this report are available on my website. #DiabetesResearch #WeightLossNews #ObesityResearch #HealthyAging #MedicalBreakthrough".